Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection

Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1463-1465. doi: 10.1016/j.dsx.2020.07.054. Epub 2020 Aug 1.

Abstract

Background and aims: The number of positive and death cases from coronavirus disease 2019 (COVID-19) is still increasing. The identification of risk factors for severe outcomes is important. Dyslipidemia has been shown as a long-known risk factor for cardiovascular disease. The aim of this study is to analyze the potential association between dyslipidemia and the severity of COVID-19 infection.

Methods: We systematically searched the PubMed database using specific keywords related to our aims until July 9th, 2020. All articles published on COVID-19 and dyslipidemia were retrieved. Statistical analysis was done using Review Manager 5.4 software.

Results: A total of 7 studies with a total of 6922 patients were included in our analysis. Our meta-analysis showed that dyslipidemia is associated with severe COVID-19 infections [RR 1.39 (95% CI 1.03-1.87), p = 0.03, I2 = 57%, random-effect modelling].

Conclusion: Dyslipidemia increases the risk of the development of severe outcomes from COVID-19 infections. Patients with dyslipidemia should be monitored closely to minimize the risk of COVID-19.

Keywords: COVID-19; Coronavirus disease 2019; Dyslipidemia; Metabolic disease; Metabolic syndrome.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections / complications*
  • Dyslipidemias / complications*
  • Humans
  • Pandemics
  • Pneumonia, Viral / complications*
  • SARS-CoV-2